Aug 18, 2021
Jnana closes $50M series B round, picks PKU as lead indication
BioWorld
© 2022 Jnana Therapeutics - All rights reserved.
BOSTON, Mass., July 8, 2022 – Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for highly validated, previously undruggable targets to treat diseases with high unmet need, will present preclinical data for its lead program, a potential first-in-class oral approach for the treatment of phenylketonuria (PKU). Data will be presented […]
BOSTON, Mass., April 26, 2022 – Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to address well-validated but hard-to-drug targets, today announced the appointment of Doug Pagán, MBA, as Chief Financial Officer and Chief Operating Officer. Mr. Pagán will be responsible for spearheading the company’s finance, operations and IT functions, including capital […]
Fierce Biotech
Pharmaceutical Business Review
Scripps Research, April 2020
Chemical and Engineering News, October 2018
This links to an external website. Merus is not responsible for any third party content.